Midazolam as a first‐line treatment for neonatal seizures: Retrospective study. Issue 5 (May 2018)

• Record Type: Journal Article
• Authors: Dao, Kim; Giannoni, Eric; Diezi, Manuel; Roulet‐Perez, Eliane; Lebon, Sebastien
• Is Part Of: Pediatrics international. Volume 60:Issue 5(2018)
• Page Start: 498
• Page End: 500
• Publication Date: 2018-05
• Subjects: anticonvulsant -- infant -- midazolam -- neonatal seizure -- phenobarbital; Pediatrics -- Periodicals; 618.92
• DOI: 10.1111/ped.13554
• Languages: English
• ISSNs: 1328-8067

Abstract

Abstract: Midazolam is commonly used to treat refractory seizures in newborns and as a first‐line anti‐epileptic drug in children. Its use as first‐line treatment of neonatal seizures has not been investigated so far. We retrospectively studied the tolerability of midazolam in 72 newborn infants who received i.v. or i.n. midazolam as first‐line treatment for seizures. No major side‐effect exclusively due to midazolam was reported. The i.n. route was used for 20 patients (27.8%). Effectiveness could not be formally evaluated due to the absence of systematic electroencephalogram recording while midazolam was administered. In conclusion, midazolam was well‐tolerated as a first‐line abortive emergency treatment of neonatal seizure. The i.n. route offers a useful alternative to i.v. phenobarbital or phenytoin in emergency settings.